ONO Pharmaceutical Co ((OPHLF)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ono Pharmaceutical Co. Ltd is conducting a clinical study titled ‘A Multicenter, Open-label, Uncontrolled Study to Evaluate the Efficacy and Safety of ONO-4538 in Patients With Richter’s Transformation.’ The study aims to assess the effectiveness and safety of ONO-4538, a drug designed to treat Richter’s Transformation, a rare and aggressive form of lymphoma.
The intervention being tested is ONO-4538, administered intravenously at a dose of 480 mg every four weeks. This drug is experimental and specifically targets patients with Richter’s Transformation.
The study is designed as an interventional, single-group assignment with no masking, focusing primarily on treatment. This straightforward design allows researchers to directly observe the effects of ONO-4538 on the participants.
The study began on April 13, 2025, with the latest update submitted on September 16, 2025. These dates are crucial as they mark the study’s progress and provide a timeline for potential results and further updates.
The ongoing study could significantly impact Ono Pharmaceutical’s stock performance and investor sentiment, especially if the results are positive. This could position the company favorably against competitors in the oncology sector.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.